Status:
RECRUITING
Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Eligibility:
All Genders
18-75 years
Brief Summary
Perioperative drug treatment has gradually become the standard regimen for locally advanced gastric cancer, whereas only a subset of patients could benefit from it. Therefore, one major challenge for ...
Detailed Description
Perioperative drug treatment has gradually become the standard regimen for locally advanced gastric cancer, whereas only a subset of patients could benefit from it. Therefore, one major challenge for ...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed locally advanced resectable gastric and gastro-oesophageal junction adenocarcinoma at the stage of cT2-T4aNxM0 (AJCC 8th) without distant metastases and without infiltration of adjacent structures and organs.
- 18-75 years old.
- Willing to provide residual tumor tissues after routine clinical diagnosis for tumor microenvironment detection analysis.
- Patients agree to participate in the study and sign the informed consent.
- Patients need to receive perioperative drug therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
Exclusion
- Human epidermal growth factor receptor 2 (HER2) is positive, that is, tissue immunohistochemical staining (IHC) (3+) or IHC (2+), and tissue fluorescence in situ hybridization (FISH) is positive.
- Patients with major cardiovascular and cerebrovascular diseases (such as congestive heart failure, unstable heart colic, atrial fibrillation, stroke, transient ischemic attack, etc.).
- Allergies or contraindications to common chemotherapy drugs, immunotherapy drugs or the ingredients.
- Women who are pregnant, breast-feeding.
- Other conditions the investigator believes that it is not suitable to participate in this study.
Key Trial Info
Start Date :
May 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
169 Patients enrolled
Trial Details
Trial ID
NCT04850729
Start Date
May 25 2021
End Date
April 1 2026
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515